HER2+ Invasive Lobular Carcinoma

HER2+ Invasive Lobular Carcinoma HER2+ invasive lobular carcinoma (ILC) is a special kind of breast cancer subtype. It means the cancer cells grow from the breast lobules to nearby tissues. This type of cancer has a lot of the HER2 protein.

Knowing about invasive lobular carcinoma HER2 positive is key. It needs special treatment because of its unique behavior. 

Understanding HER2+ Invasive Lobular Carcinoma

HER2 positive cancer, especially in invasive lobular carcinoma, is a special kind of breast cancer. It has too many HER2 protein receptors. This makes cancer cells grow faster. It needs special treatment because it’s more aggressive.

---

Get Free Consultation

Please enable JavaScript in your browser to complete this form.

- Step 1 of 4

Select Your Gender *

• Woman
• Man

Next

Select Your Age

Age: 0

Next

When do you plan on getting The Treatment? *

• As Soon
• 3 Months
• 1 Year
• Only Info

Next

What is your name? *

Dropdown *Select Your TreatmentCheck-upEar Nose ThroatCardiovascular SurgeryMedical OncologyDentistryNutrition and DieteticsPediatricsDermatologyPhysical Therapy and RehabilitationGeneral SurgeryOphtalmologyInternal MedicineObstetrics and GynecologyWeight Loss SurgeryOrthopedics Traumatology and Sport InjuriesNeurologyNeurosurgeryRadiation OncologyEndoscopyCardiologyRadiologyUrologyOrgan TransplantationHematologyAesthetic Plastic and Reconstructive SurgeryBone Marrow TransplantationIVF

Phone *

What is your email? *

Paragraph Text

Get Your Consultation

---

ACIBADEM Health Point: The Future of Healthcare

We believe that everyone deserves access to quality healthcare, which is why we have established multiple branches in strategic locations. Whether you're in need of routine check-ups, specialized treatments, or emergency care, ACIBADEM Health Point is here for you.

---

What is HER2+ Invasive Lobular Carcinoma?

Invasive lobular carcinoma HER2 positive starts in the lobules, which make milk. These tumors have lots of HER2 receptors. This makes them grow faster. Knowing this helps doctors treat it better.

Characteristics of HER2+ Tumors

HER2 positive cancer cells are different from other breast cancers. They have:

• Rapid growth and proliferation due to the overexpression of HER2 proteins.
• Increased likelihood of recurrence and metastasis compared to HER2-negative tumors.
• Enhanced response to specific HER2-targeted therapies, providing a pathway for effective treatment strategies.

Understanding these traits helps doctors make better treatments for HER2 positive invasive lobular carcinoma.

Breast Cancer Subtypes: Focus on Lobular Breast Cancer

It’s key to know about different breast cancer types for better treatment. Lobular breast cancer is special because it’s hard to find and treat. It has its own way of growing and reacting to treatments, especially with HER2 positivity.

Difference Between Invasive Ductal and Invasive Lobular Carcinoma

Lobular breast cancer is not as common as invasive ductal carcinoma. It grows differently, spreading out more than forming a lump. This makes it harder to spot early, which is important for treatment.

Significance of HER2 Positivity

HER2 positivity in lobular breast cancer makes treatment harder. These tumors grow fast and are aggressive. But, they don’t always react the same way to treatments as other HER2-positive cancers. This means doctors need to think carefully about how to treat them.

Knowing about these differences helps doctors make better treatment plans. It leads to more tailored care for each patient.

Diagnosis Methods for HER2+ Invasive Lobular Carcinoma

Finding out early if you have HER2 positive cancer is key for good treatment. Doctors use special tests to make sure they find it right. This helps plan the best treatment.

Mammography is a basic test that looks for changes in the breast. But, invasive lobular carcinoma can be hard to spot. That’s why more tests are needed to confirm if it’s HER2 positive. A biopsy is very important here.

A biopsy takes a piece of the tumor for closer look. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are key tests. They check for HER2 proteins or if the HER2 gene is too active.

• Immunohistochemistry (IHC): This test stains the tissue with HER2 antibodies. If it’s positive, it means the tissue has too much HER2 protein.
• Fluorescence In Situ Hybridization (FISH): This test looks for HER2 gene copies in cancer cells. It helps understand the cancer’s genetic makeup.

These tests not only confirm HER2 positive cancer. They also help doctors choose the right treatment. This makes treatment more effective for people with invasive lobular carcinoma HER2 positive.

Invasive Lobular Carcinoma HER2 Positive: Treatment Options

Invasive lobular carcinoma HER2 positive is a special kind of breast cancer. It needs a special way to be treated. The main treatments are surgery, chemotherapy, and targeted therapies. These treatments work together to kill cancer cells and stop them from coming back.

Surgery

Surgery is the first step in treating this cancer. It might be a lumpectomy or mastectomy, based on the tumor size and where it is. The goal is to remove all cancer and save as much healthy tissue as possible.

This helps lower the risk of the cancer coming back. It also makes other treatments work better.

Chemotherapy

After surgery, chemotherapy is often given to lower the chance of the cancer coming back. It uses drugs that kill fast-growing cancer cells. The type of chemotherapy depends on the tumor size, the patient’s health, and any treatments they’ve had before.

Chemotherapy is a key part of treating HER2 positive breast cancer. It helps get rid of any cancer cells left behind.

Targeted Therapies

Targeted therapies are a big hope for treating invasive lobular carcinoma HER2 positive. They target the HER2 receptor that this cancer type has too much of. Drugs like trastuzumab (Herceptin) and pertuzumab (Perjeta) have been shown to greatly improve outcomes for HER2 positive patients.

These therapies work by stopping the HER2 protein from helping cancer cells grow and survive. Adding them to treatment plans is a big step forward in fighting cancer.

Targeted Therapies and Clinical Trials

Targeted therapies have changed how we treat HER2 positive breast cancer. Herceptin and Perjeta are now key treatments. They target the HER2 protein on cancer cells.

These treatments stop cancer cells from growing. They do this by blocking signals that tell cancer cells to grow.

Current Targeted Therapies

Herceptin and Perjeta are big names in fighting HER2 positive breast cancer. They have greatly improved patient outcomes. Now, patients have a better chance of beating the disease.

New treatments like Kadcyla are also being used. Kadcyla delivers medicine right to cancer cells. This makes treatments more effective and less harsh than old chemotherapy.

Ongoing Clinical Trials

Clinical trials are key to making HER2 positive breast cancer treatments better. They test new drugs and treatment mixes. This helps us find better ways to fight cancer.

Researchers are looking into treatments that target more than one thing at once. They also want to make treatments more personal to each patient. Joining clinical trials means getting new treatments that could soon be standard care.

Prognosis for Patients with HER2+ Invasive Lobular Carcinoma

The prognosis for HER2 positive cancer, like invasive lobular breast cancer, has gotten better over time. This is thanks to new treatments that target the cancer well. These treatments have made managing the disease much more effective.

Many things affect how well patients with HER2+ invasive lobular carcinoma will do. These include the size and grade of the tumor, and how well the treatment works. Making treatment plans that fit each patient has greatly improved survival chances. Here’s a table that shows what affects the prognosis:

Now, doctors can make treatments that match the unique needs of HER2 positive cancer. This has made managing lobular breast cancer much better. So, people diagnosed today have a much better outlook than before. This shows how important ongoing research and new treatments are.

Hormone Receptor Positive Breast Cancer in HER2+ Cases

When dealing with HER2+ invasive lobular carcinoma that also expresses hormone receptors, a multifaceted treatment approach can yield the best outcomes. Combining hormone treatments with HER2-targeted therapies can be especially effective in such hormone receptor positive breast cancer cases. Endocrine therapy options, customized based on the patient’s menopausal status and other individual factors, include tamoxifen and aromatase inhibitors.

Combination Therapies

Combination therapies are increasingly being used to treat hormone receptor positive breast cancer in HER2+ cases. This approach involves integrating hormone treatments such as tamoxifen or aromatase inhibitors with targeted therapies like trastuzumab (Herceptin) or lapatinib. By addressing both hormonal and HER2 pathways, these combination therapies can significantly improve patient outcomes, particularly in cases where single-modality treatments may be less effective.

Hormone Treatments

Hormone treatments remain a cornerstone in managing hormone receptor positive breast cancer. In HER2+ cases, the use of tamoxifen is common for premenopausal women, while postmenopausal women may benefit from aromatase inhibitors. These hormone treatments help block the effects of estrogen on breast tissue, thereby slowing the growth of hormone receptor positive breast cancer. When used in conjunction with HER2-targeted therapies, hormone treatments can provide a comprehensive approach, optimizing the therapeutic efficacy and enhancing long-term prognosis.

The Role of Acibadem Healthcare Group in Treating HER2+ Invasive Lobular Carcinoma

The Acibadem Healthcare Group is known for its top-notch care for invasive lobular carcinoma HER2 positive. They use the latest tools and follow the best treatment plans from around the world.

Patients with HER2+ invasive lobular carcinoma get care that fits their unique needs at Acibadem Healthcare Group. This means better treatment results for those seeking expert care for this cancer type.

Acibadem Healthcare Group has a team of experts and the newest medical tech. They lead in treating invasive lobular carcinoma HER2 positive. They offer hope and better chances for recovery to many with this breast cancer.

Updates in Research for HER2+ Invasive Lobular Carcinoma

The study of HER2 positive breast cancer is changing fast. New findings and future plans are exciting. Studies now look at changes in genes and how they affect treatment.

Recent Studies

New studies show how looking at genes helps in treating HER2 positive breast cancer. They found certain changes in genes that help predict how well treatments work. Also, they found new markers that could lead to better treatments for each patient.

This research is building a base for making drugs that target cancer better. This could mean better results for patients.

Future Directions

Looking ahead, research is focusing on new ways to fight cancer. Things like vaccine therapy and immunotherapy could change the game. These methods use the body’s immune system to fight cancer better.

Using gene data in treatment will be key to improving care for HER2+ invasive lobular carcinoma.

Patient Support and Resources

For people with HER2 positive cancer, getting help is key. Patient support includes counseling to help with feelings. There are special breast cancer resources for HER2 positive folks. They help with treatment choices, side effects, and more.

Handling money matters is also important in patient support. Many patients worry about treatment costs. Getting help with money and understanding insurance can make things easier.

Survivor networks are a big part of support. They offer a community and shared stories. Being in groups with others who have HER2 positive cancer can make you feel less alone.

• Emotional Counseling
• Financial Guidance
• Survivor Networks

There are many breast cancer resources to help during treatment. They give info and support. Patients get to know a community that cares.

For those with HER2 positive cancer, getting full patient support and breast cancer resources really helps. It makes a big difference in their treatment journey.

Key Takeaways for HER2+ Invasive Lobular Carcinoma Management

Understanding HER2+ invasive lobular carcinoma is key. It’s important to know its unique traits and how to manage it. Early detection is crucial for better treatment and fewer complications.

Advanced tests like imaging and biopsy help find the cancer accurately. This makes treatment more effective.

Managing HER2+ invasive lobular carcinoma requires a mix of treatments. Surgery, chemotherapy, and targeted therapies like trastuzumab (Herceptin) help a lot. Adding hormone treatments for hormone-positive cases is also important.

It’s vital to keep up with new treatments through clinical trials. This helps patients get the best care.

But it’s not just about medicine. Patients need strong support systems. Groups like Acibadem Healthcare Group offer help. Keeping up with research means we can improve life quality and survival chances.

Combining new medical treatments, personalized care, and ongoing support is key. This approach helps manage HER2+ invasive lobular carcinoma well.

FAQ